Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Erlotinib + Gemcitabine/Platinum in First-Line NSCLC
NCT01998919Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2006
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tarceva + Gem/Plat with Placebo + Gem/Plat (2 arms). Primary endpoint: Percentage of Participants With Non-Progression at 8 weeks. Started Aug 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01998919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998919.